Bristol Myers Squibb Co. said on Friday it will acquire drug developer Turning Point Therapeutics Inc. for $4.1 billion in cash to help bolster its arsenal of cancer drugs. Turning Point's lead drug, repotrectinib, targets mutations in certain proteins in ...